PLD2 Forms a Functional Complex with Mtor/Raptor to Transduce Mitogenic Signals
Total Page:16
File Type:pdf, Size:1020Kb
Cellular Signalling 18 (2006) 2283–2291 www.elsevier.com/locate/cellsig PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals Sang Hoon Ha a, Do-Hyung Kim b, Il-Shin Kim a, Jung Hwan Kim a, Mi Nam Lee a, Hyun Ju Lee a, Jong Heon Kim a, Sung Key Jang a, Pann-Ghill Suh a, Sung Ho Ryu a,⁎ a Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, Kyungbook 790-784, Republic of Korea b Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA Received 26 April 2006; received in revised form 11 May 2006; accepted 11 May 2006 Available online 3 June 2006 Abstract Mammalian target-of-rapamycin (mTOR), which is a master controller of cell growth, senses a mitogenic signal in part through the lipid second messenger phosphatidic acid (PA), generated by phospholipase D (PLD). To understand further which isozymes of PLD are involved in this process, we compared the effect of PLD isozymes on mTOR activation. We found that PLD2 has an essential role in mitogen-induced mTOR activation as the siRNA-mediated knockdown of PLD2, not of PLD1, profoundly reduced the phosphorylations of S6K1 and 4EBP1, well-known mTOR effectors. Furthermore, exogenous PA-induced mTOR activation was abrogated by PLD2 knockdown, but not by PLD1 knockdown. This abrogation was found to be the result of complex formation between PLD2 and mTOR/raptor. PLD2 possesses a TOS-like motif (Phe-Glu-Val-Gln-Val, a.a. 265– 269), through which it interacts with raptor independently of the other TOS motif-containing proteins, S6K1 and 4EBP1. PLD2-dependent mTOR activation appears to require PLD2 binding to mTOR/raptor with lipase activity, since lipase-inactive PLD2 cannot trigger mTOR activation despite its ability to interact with mTOR/raptor. Abrogation of mitogen-dependent mTOR activation by PLD2 knockdown was rescued only by wild type PLD2, but not by raptor binding-deficient and lipase-inactive PLD2. Our results demonstrate the importance of localized PA generation for the mitogen-induced activation of mTOR, which is achieved by a specific interaction between PLD2 and mTOR/raptor. © 2006 Elsevier Inc. All rights reserved. Keywords: PLD2; mTOR; Raptor; Complex formation 1. Introduction based on sequence similarity of their catalytic domains [4,5]. The mTOR pathway is an emerging target for the treatment of cancer, Mammalian target-of-rapamycin (mTOR) is a serine/threonine diabetes and obesity [6–10], and recent studies have demonstrated protein kinase [1–3] and a member of a novel superfamily of its role as a mediator of lifespan control in C. elegans [11] and signaling proteins termed PI 3-kinase related kinases (PIKKs), Drosophila [12]. Despite the significance of this pathway in such diverse biological processes, the mechanism of its regulation by upstream signals remains to be addressed. Recently, significant Abbreviations: mTOR, mammalian target-of-rapamycin; PLD, phospholipase D; raptor, regulatory associated for mTOR; PIKK, phosphatidylinositol 3-kinase- progress was made in our understanding of the regulatory related protein kinase; Rheb, Ras enriched in brain; PC, phosphatidylcholine; PA, mechanisms of mTOR signaling and this revealed the participa- phosphatidic acid; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propa- tion of the mTOR complex (mTOR/raptor) containing raptor nesulfonic acid; EMEM, Dulbecco's modified Eagle's medium; EDTA, ethylene [13,14] and GβL [15] in response to upstream signals for the diamine tetraacetic acid; PMSF, phenylmethlysulfonyl fluoride; PAGE, polyacryl- appropriate control of cell growth and the other mTOR complex amide gel electrophoresis; BCS, bovine calf serum; FBS, fetal bovine serum; PBS, phosphate buffered saline; DTT, dithiothreitol. (mTOR/rictor) containing rictor [16] and GβL [15] for the control ⁎ Corresponding author. Tel.: +82 54 279 2292; fax: +82 54 279 0645. of actin cytoskeleton. These upstream signals derived from E-mail address: [email protected] (S.H. Ryu). insulin, nutrients, and/or mitogens are likely to be mediated by the 0898-6568/$ - see front matter © 2006 Elsevier Inc. All rights reserved. doi:10.1016/j.cellsig.2006.05.021 2284 S.H. Ha et al. / Cellular Signalling 18 (2006) 2283–2291 tuberous sclerosis complex 1/2 [17] and Rheb [18–22]. Though 5′-UGC UCA UUG UCG UCC CAC CUU-3′, which correspond to human the functional connection between mTOR complex and these PLD1a coding nucleotides 1455–1475. All siRNA sequences were subjected to BLAST in the NCBI database and complete matches were only found for PLD2 upstream regulators is known, their physical connection is not sequences. Luciferase GL2 duplex was purchased from Dharmacon Research, completely understood [6–9]. Recently, Rheb was shown to Inc. and was used as a negative control. For add-back experiment for PLD2 interact with mTOR/raptor and activate kinase activity of mTOR silencing, three residues of human PLD2 cDNA (nucleotides 703–723 of PLD2; [23,24]. AAGAGGTGGCTGGTGGTGAAG) are substituted to AAGAGATGGCTAG wt In addition, mTOR requires the lipid second messenger TAGTGAAG for add back mutants of PLD2 [31]. This mutation is silencing mutations. This gene is subcloned into mammalian expression vector pcDNA3.1 phosphatidic acid (PA) for its activation [25,26]. PA is an enzy- (Invitrogen) and digested with restriction enzymes KpnI and XbaI. These matic product of phospholipase D (PLD) [27,28]. Mammalian mutations are confirmed through nucleotide sequence analysis. PLD isozymes identified to date, PLD1 and PLD2, sense a variety of signals, such as neurotransmitters, hormones and 2.4. Cell culture and plasmid/siRNA transfection growth factors, to regulate multiple physiological events such as proliferation, secretion, respiratory burst and actin cytoskeletal COS7 cells were maintained in a 5% CO2 humidified atmosphere at 37 °C reorganization [27,28]. Here, our effort to elucidate which iso- and fed DMEM supplemented with 10% bovine calf serum. HEK293 cells and OVCAR-3 cells were fed DMEM supplemented with 10% fetal bovine serum. zyme is mainly involved in mitogen-induced mTOR activation Cells grown on tissue culture dishes was transiently transfected using identifies that PLD2 is a major isozyme to transduce mitogenic LipofectAMINE, as described previously [31,32]. Cells were allowed to express signaling to mTOR/raptor and this is achieved by complex the recombinant proteins for 24 h after transfection and then deprived of serum formation between PLD2 and mTOR/raptor. As a result, we for additional 24 h. The cells were then subjected to co-immunoprecipitation suggest the physical/functional connections between mitogen- analysis. For knockdown with siRNA, cells were grown for 36–48 h before serum deprivation. induced PA generation and its effector mTOR and would pro- vide further insight into mTOR-related metabolic diseases such 2.5. Co-immunoprecipitation as cancer, diabetes and obesity. After harvesting COS7 cells, total extracts were prepared by brief sonication 2. Materials and methods in ice-cold lysis buffer (40 mM HEPES pH7.5, 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 2.1. Materials 0.5% CHAPS, 1 mM PMSF, protease inhibitor cocktails) [13]. Clarified extracts were mixed with 2 μg of the respective antibodies. Then protein A-Sepharose The enhanced chemiluminescence kit and dipalmitoylphosphatidyl beads were added to isolate the antibody complex. After four washings with lysis [methyl-3H]choline were purchased from Amersham Biosciences. Horseradish buffer, the final immunoprecipitates were washed once with wash buffer (50 mM peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgA, IgM, and HEPES pH7.5, 150 mM NaCl), and then subjected to SDS-PAGE. IgG were from Kirkegaard and Perry Laboratories, Inc. (Gaithersburg, MD). Polyclonal antibody was raised against PLD as previously described [29]. 2.6. Western blot analysis Antibodies against mTOR, pS6K1 (pThr 389), S6K1, p4EBP1(pThr 37/46), and 4EBP1 and rapamycin were from Cell Signaling. Protein A-Sepharose was from Proteins were separated by SDS-PAGE on 8–16% gradient gels, and the RepliGen (Needham, MA). CHAPS was from Sigma. Dulbecco's modified separated proteins were transferred onto nitrocellulose membranes and blocked Eagle's medium (DMEM) and LipofectAMINE were from Invitrogen. C-6 with TTBS buffer (10 mM Tris–HCl, pH 7.6, 150 mM NaCl, and 0.05% Tween- phosphatidic acid was from Avanti, and recombinant 4EBP1 was purchased from 20) containing 5% skimmed milk powder. Membranes were then incubated with Stratagen. primary antibody at the concentration recommended by the manufacturer for 4 h at room temperature. Unbound antibody was washed away with TTBS buffer. 2.2. Plasmids Membranes were subsequently incubated with horseradish peroxidase-conju- gated secondary antibody for 1 h at room temperature, washed five times with Mammalian expression vectors for PLD1wt,PLD2wt,PLD2ΔN184, TTBS buffer, and developed using an ECL system. PLD2ΔN308, and PLD2K758R were used as described previously [30–32]. Ex- pression vectors for HA–mTORwt, myc–mTORwt, myc–raptorwt, HA–raptorwt 2.7. In vivo PLD assay and HA–raptor194YDC/AAAmt were gifts from Dr. David M. Sabatini (MIT) [13]. To introduce the TOS motif mutation in PLD2, pCDNA3.1(+)/PLD2 containing In vivo PLD activity was assayed by measuring the formation of wild type PLD2 was PCR amplified using the following oligomers; sense phosphatidyl–butanol as described previously [32]. In brief, cells were loaded (5′GGC CGA GAC CAA GTT TGT TAT CGC3′), antisense (F265A:5′CCA with [3H]myristic acid (2 μCi/ml) for 8 h and then washed twice with DMEM. TCG ATC CGC ACG CCG TGC CGT GCC TCC GTG CTC CTT TTC CCC Labeled cells were incubated with 0.4% butanol for 10 min to measure basal ACT TGC ACC TCA GCG CCA GG3′), antisense (E266R: 5′CCA TCG ATC PLD activity. Total lipids were extracted with 1.2 ml of methanol:1 M NaCl: CGC ACG CCG TGC CGT GCC TCC GTG CTC CTT TTC CCC ACT TGC chloroform (1:1:1 by volume) and then separated by thin-layer chromatography ACC CTA AAG CCA GG3′).